Hypertension News and Research RSS Feed - Hypertension News and Research

Study: Viagra, other related drugs not a universal 'cure-all' for impotence

Study: Viagra, other related drugs not a universal 'cure-all' for impotence

Viagra and other related drugs are not a universal 'cure-all' for impotence, according to a new study from The University of Manchester and NatCen Social Research. [More]
Cedars-Sinai Heart Institute sets new national standard for most adult heart transplants

Cedars-Sinai Heart Institute sets new national standard for most adult heart transplants

The Cedars-Sinai Heart Institute completed 120 adult heart transplants and two adult heart-lung transplants in 2014, setting a new national standard for the most adult heart transplants performed in a single year. [More]
CVS Health Foundation announces new grant recipients to increase access to health care

CVS Health Foundation announces new grant recipients to increase access to health care

The CVS Health Foundation, a private foundation created by CVS Health Corporation (NYSE: CVS), today announced 55 new grant recipients as part of its multi-year, $5 million commitment to increase access to health care in communities nationwide. [More]
Survey reveals growing needs, challenges faced by health plans serving vulnerable populations

Survey reveals growing needs, challenges faced by health plans serving vulnerable populations

Health Integrated, a leader in precision care management solutions, released the results today of an annual health plan survey jointly commissioned with the Association for Community Affiliated Plans, a national trade association representing nonprofit safety net health plans. [More]
Actavis seeks FDA marketing approval for Ambrisentan Tablets, 5 mg and 10 mg

Actavis seeks FDA marketing approval for Ambrisentan Tablets, 5 mg and 10 mg

Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market Ambrisentan Tablets, 5 mg and 10 mg. [More]
BP monitoring essential for early diagnosis, management of hypertensive disorders in pregnancy

BP monitoring essential for early diagnosis, management of hypertensive disorders in pregnancy

Accurate blood pressure measurement (BP) is fundamental to the early diagnosis of hypertensive disorders in pregnancy, says a review published 1 April, 2015, in The Obstetrician & Gynaecologist (TOG). [More]
Astellas Pharma, Medivation announce topline results from enzalutamide Phase 2 STRIVE trial

Astellas Pharma, Medivation announce topline results from enzalutamide Phase 2 STRIVE trial

Astellas Pharma Inc. and Medivation, Inc. today announced topline results from the Phase 2 STRIVE trial comparing enzalutamide with bicalutamide in a study population of men with non-metastatic or metastatic castration-resistant prostate cancer. [More]
Combined therapy boosts growth in short children with low IGF-1

Combined therapy boosts growth in short children with low IGF-1

Children with short stature benefit from receiving combined treatment with growth hormone and insulin-like growth factor-1, if they have low endogenous levels of the latter, a study shows. [More]
Research breakthrough could help develop tools to repair damaged nerve cells

Research breakthrough could help develop tools to repair damaged nerve cells

A team of researchers at the IRCM led by Frédéric Charron, PhD, in collaboration with bioengineers at McGill University, uncovered a new kind of synergy in the development of the nervous system, which explains an important mechanism required for neural circuits to form properly. [More]
MOVANTIK (naloxegol) now available in U.S. for treatment of OIC in adult patients with non-cancer pain

MOVANTIK (naloxegol) now available in U.S. for treatment of OIC in adult patients with non-cancer pain

Nektar Therapeutics reported that partner AstraZeneca announced today that MOVANTIK (naloxegol) has launched in the United States. On September 16, 2014, the US Food and Drug Administration (FDA) approved MOVANTIK as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain. [More]
Mylan announces U.S. launch of Amlodipine and Valsartan Tablets

Mylan announces U.S. launch of Amlodipine and Valsartan Tablets

Mylan N.V. today announced the U.S. launch of Amlodipine and Valsartan Tablets, 5 mg/160 mg, 5 mg/320 mg, 10 mg/160 mg, 10 mg/320 mg, which is the generic version of Novartis' Exforge Tablets. [More]
Amgen receives FDA priority review designation for Kyprolis to treat relapsed multiple myeloma

Amgen receives FDA priority review designation for Kyprolis to treat relapsed multiple myeloma

Amgen today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) of Kyprolis® (carfilzomib) for Injection for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy. [More]
Alternating sunitinib, everolimus not supported in advanced RCC

Alternating sunitinib, everolimus not supported in advanced RCC

Australian researchers report that an alternating regimen of sunitinib and everolimus, although feasible and low-risk in patients with advanced renal cell carcinoma, failed to meet the prespecified criteria for use or continued development. [More]
HRQoL benefit of alternative sunitinib dosing schedule in RCC patients

HRQoL benefit of alternative sunitinib dosing schedule in RCC patients

Patients with metastatic renal cell carcinoma reported a marked improvement in their health-related quality of life when given sunitinib on a 2 weeks on and 1 week off schedule compared with a 4 weeks on and 2 weeks off regimen, a Japanese study finds. [More]
Angiotensin system inhibitor use improves metastatic RCC survival outcomes

Angiotensin system inhibitor use improves metastatic RCC survival outcomes

Use of angiotensin system inhibitors is associated with significant survival benefits in metastatic renal cell carcinoma patients treated in the targeted therapy era, research findings indicate. [More]
Qualcomm Life, AMC Health to accelerate transformation of health care delivery for at-risk patients

Qualcomm Life, AMC Health to accelerate transformation of health care delivery for at-risk patients

Qualcomm Life, Inc., a subsidiary of Qualcomm Incorporated, and AMC Health, a privately held provider of 'real-time' patient management solutions, today announced a collaborative effort to accelerate the transformation of chronic care and population health management by significantly enhancing connectivity and care coordination for at-risk patients, specifically those with heart failure, hypertension, diabetes, asthma or COPD, in a cost-effective manner. [More]
Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced its plans for the commercialization of SPRIX (ketorolac tromethamine) Nasal Spray and OXAYDO (oxycodone HCI, USP) tablets for oral use only –CII. [More]
Women who give birth to four or more children at risk of heart disease

Women who give birth to four or more children at risk of heart disease

Women who give birth to four or more children are more likely to have cardiovascular changes that can be early indicators of heart disease than women who have fewer children, new research by UT Southwestern Medical Center cardiologists finds. [More]
New research shows spinal surgery improves sexual function, reduces low back pain

New research shows spinal surgery improves sexual function, reduces low back pain

Chronic low back pain can limit everyday activities, including sex. New research presented today at the 2015 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS), found that 70 percent of patients consider sexual activity "relevant" to their life quality, and patients who receive surgical treatment for spinal spondylolisthesis (DS) and spinal stenosis (SS)--common degenerative conditions most often occurring in older adults--were twice as likely to report no pain during sex. [More]
Home-exercise plan for HIV patients

Home-exercise plan for HIV patients

In addition to antiretroviral medications, people with HIV may soon begin receiving a home exercise plan from their doctors, according to a researcher at Case Western Reserve University's Frances Payne Bolton School of Nursing. [More]
Advertisement
Advertisement